董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Pyott | 男 | Director | 73 | 9.01万美元 | 12.56 | 2025-12-15 |
| Suzanne Bruhn | 女 | Director | 62 | 8.76万美元 | 15.52 | 2025-12-15 |
| Thomas McCourt | 男 | Director | 68 | 9.01万美元 | 9.28 | 2025-12-15 |
| Steve Krognes | 男 | Director | 57 | 9.51万美元 | 6.57 | 2025-12-15 |
| Bernard Coulie | 男 | President,Chief Executive Officer and Director | 60 | 546.29万美元 | 250.53 | 2025-12-15 |
| John Curnutte | 男 | Director | 74 | 8.26万美元 | 14.94 | 2025-12-15 |
| Darren Cline | 男 | Director | 61 | 9.01万美元 | 9.28 | 2025-12-15 |
| Katharine Knobil | 女 | Director | 62 | 9.51万美元 | 10.08 | 2025-12-15 |
| Hoyoung Huh | 男 | Chairman of the Board, Director | 56 | 11.26万美元 | 19.88 | 2025-12-15 |
| Gayle Crowell | 女 | Director | 75 | 9.51万美元 | 12.42 | 2025-12-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bernard Coulie | 男 | President,Chief Executive Officer and Director | 60 | 546.29万美元 | 250.53 | 2025-12-15 |
| Keith Cummings | 男 | Chief Financial Officer | 49 | 239.73万美元 | 74.82 | 2025-12-15 |
| Lily Cheung | 女 | Chief Human Resources Officer | -- | 未披露 | 20.24 | 2025-12-15 |
| Minnie Kuo | 女 | Chief Operating Officer | 45 | 154.29万美元 | 19.08 | 2025-12-15 |
董事简历
中英对照 | 中文 | 英文- David Pyott
-
David Pyott,Allergan公司的前任主席（2001年至2015年）、首席执行官（1998年至2015年）、Avery Dennison Corporation的现任董事（1999年以来）、其首席独立董事（2010年以来）、Alnylam Pharmaceuticals公司、BioMarin Pharmaceutical公司的董事会成员、Chapman University监事会的成员、Ophthalmology Foundation的理事会成员、the Foundation of the American Academy of Ophthalmology的咨询委员会的成员。
David Pyott,Former Chairman and Chief Executive Officer of Allergan, Inc. and former Lead Director of Avery Dennison Corporation. Currently member of the Board of Directors of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc. and Pliant Therapeutics. Chairman of the Governing Board of London Business School, member of the Board of Trustees and Executive Committee of the California Institute of Technology, Vice President of the Ophthalmology Foundation and President of the Advisory Board of the Foundation of the American Academy of Ophthalmology. - David Pyott,Allergan公司的前任主席（2001年至2015年）、首席执行官（1998年至2015年）、Avery Dennison Corporation的现任董事（1999年以来）、其首席独立董事（2010年以来）、Alnylam Pharmaceuticals公司、BioMarin Pharmaceutical公司的董事会成员、Chapman University监事会的成员、Ophthalmology Foundation的理事会成员、the Foundation of the American Academy of Ophthalmology的咨询委员会的成员。
- David Pyott,Former Chairman and Chief Executive Officer of Allergan, Inc. and former Lead Director of Avery Dennison Corporation. Currently member of the Board of Directors of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc. and Pliant Therapeutics. Chairman of the Governing Board of London Business School, member of the Board of Trustees and Executive Committee of the California Institute of Technology, Vice President of the Ophthalmology Foundation and President of the Advisory Board of the Foundation of the American Academy of Ophthalmology.
- Suzanne Bruhn
-
Suzanne Bruhn自2017年2月起担任董事。Bruhn博士自2019年5月起担任Tiaki Therapeutics Inc.的总裁兼首席执行官。Bruhn博士此前曾于2017年4月至2018年9月担任Proclara Biosciences，Inc.的总裁兼首席执行官。2012年5月至2015年11月，Bruhn博士曾担任ProMedior，Inc.的总裁兼首席执行官。在此之前，Bruhn博士于1998年12月至2012年2月在Shire plc（一家公开上市的生物制药公司）担任高级副总裁，战略规划和项目管理。Bruhn博士曾在上市制药公司Raptor Pharmaceuticals Corp.和Novelion Therapeutics，Inc.的董事会任职，Bruhn博士目前在Pliant Therapeutics和Retrophin，Inc.的董事会任职Bruhn博士在爱荷华州立大学（Iowa State University）获得化学学士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学博士学位。
Suzanne Bruhn, has served as a member of our board of directors since July 2016. Dr. Bruhn currently serves as President and Chief Executive Officer of Tiaki Therapeutics, a preclinical biotechnology company, since May 2019. Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences, Inc, a clinical-stage biotechnology company, from April 2017 until September 2018. Prior to Proclara, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc., a private clinical-stage biotech company developing targeted therapies to treat diseases involving fibrosis, from May 2012 until November 2015. She currently also serves on the board of directors of Travere Therapeutics, Inc., a publicly traded pharmaceutical company, from April 2020 and Cerecor Inc., a publicly traded pharmaceutical company, from April 2020. She previously served as a member of the board of directors of Aeglea BioTherapeutics, Inc, a publicly traded biotherapeutics company, from February 2017 through August 2020 Novelion Therapeutics, Inc, a publicly traded pharmaceutical company, from October 2017 through January 2020 and Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. She holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Chemistry from Massachusetts Institute of Technology and completed her postdoctoral fellowship in the department of human genetics at Harvard Medical School. - Suzanne Bruhn自2017年2月起担任董事。Bruhn博士自2019年5月起担任Tiaki Therapeutics Inc.的总裁兼首席执行官。Bruhn博士此前曾于2017年4月至2018年9月担任Proclara Biosciences，Inc.的总裁兼首席执行官。2012年5月至2015年11月，Bruhn博士曾担任ProMedior，Inc.的总裁兼首席执行官。在此之前，Bruhn博士于1998年12月至2012年2月在Shire plc（一家公开上市的生物制药公司）担任高级副总裁，战略规划和项目管理。Bruhn博士曾在上市制药公司Raptor Pharmaceuticals Corp.和Novelion Therapeutics，Inc.的董事会任职，Bruhn博士目前在Pliant Therapeutics和Retrophin，Inc.的董事会任职Bruhn博士在爱荷华州立大学（Iowa State University）获得化学学士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学博士学位。
- Suzanne Bruhn, has served as a member of our board of directors since July 2016. Dr. Bruhn currently serves as President and Chief Executive Officer of Tiaki Therapeutics, a preclinical biotechnology company, since May 2019. Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences, Inc, a clinical-stage biotechnology company, from April 2017 until September 2018. Prior to Proclara, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc., a private clinical-stage biotech company developing targeted therapies to treat diseases involving fibrosis, from May 2012 until November 2015. She currently also serves on the board of directors of Travere Therapeutics, Inc., a publicly traded pharmaceutical company, from April 2020 and Cerecor Inc., a publicly traded pharmaceutical company, from April 2020. She previously served as a member of the board of directors of Aeglea BioTherapeutics, Inc, a publicly traded biotherapeutics company, from February 2017 through August 2020 Novelion Therapeutics, Inc, a publicly traded pharmaceutical company, from October 2017 through January 2020 and Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. She holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Chemistry from Massachusetts Institute of Technology and completed her postdoctoral fellowship in the department of human genetics at Harvard Medical School.
- Thomas McCourt
-
Thomas McCourt自2016年7月以来一直担任我们的董事会成员。McCourt先生自2009年加入Ironwood以来一直担任市场营销与销售的高级副总裁和IronwoodPharmaceuticals，Inc.的首席商务官。在加入Ironwood之前，McCourt先生于2008年4月至2009年8月离开了DeNosumab在安进公司的美国品牌团队。在此之前，McCourt从2001年到2008年在Novartis AG任职，指导Zelnorm的推出和增长，用于治疗IBS-C和CIC患者，并担任多个高级商业职位，包括战略营销和运营的Vice President。McCourt先生也是Astra Merck Inc.的创始团队成员，领导医疗事务和科学联络组的发展，然后担任PriloSec™；和Nexium®；的品牌经理。McCourt先生拥有威斯康星大学（University of Wisconsin）的药学学位。
Thomas McCourt,has served on Pliant Therapeutics, Inc. Board since March 2023. Mr. McCourt currently serves as Chief Executive Officer and member of the board of directors of Ironwood Pharmaceuticals, Inc., a biopharmaceutical company focused on gastrointestinal therapies, where he has served since June 2021. Mr. McCourt had previously served as President and Interim Chief Executive Officer of Ironwood from March 2021 to June 2021 and as President from April 2019 to June 2021. Prior to April 2019, Mr. McCourt served as Ironwood's Senior Vice President of marketing and sales and Chief Commercial Officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from 2008 to 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he held a number of senior commercial roles, including Vice President of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra-Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager. Mr. McCourt serves on the board of trustees for the American Society of Gastrointestinal Endoscopy. Mr. McCourt previously served on the board of directors of Acceleron Pharma Inc. prior to its acquisition by Merck in November 2021. Mr. McCourt received a B.S. in Pharmacy from the University of Wisconsin. - Thomas McCourt自2016年7月以来一直担任我们的董事会成员。McCourt先生自2009年加入Ironwood以来一直担任市场营销与销售的高级副总裁和IronwoodPharmaceuticals，Inc.的首席商务官。在加入Ironwood之前，McCourt先生于2008年4月至2009年8月离开了DeNosumab在安进公司的美国品牌团队。在此之前，McCourt从2001年到2008年在Novartis AG任职，指导Zelnorm的推出和增长，用于治疗IBS-C和CIC患者，并担任多个高级商业职位，包括战略营销和运营的Vice President。McCourt先生也是Astra Merck Inc.的创始团队成员，领导医疗事务和科学联络组的发展，然后担任PriloSec™；和Nexium®；的品牌经理。McCourt先生拥有威斯康星大学（University of Wisconsin）的药学学位。
- Thomas McCourt,has served on Pliant Therapeutics, Inc. Board since March 2023. Mr. McCourt currently serves as Chief Executive Officer and member of the board of directors of Ironwood Pharmaceuticals, Inc., a biopharmaceutical company focused on gastrointestinal therapies, where he has served since June 2021. Mr. McCourt had previously served as President and Interim Chief Executive Officer of Ironwood from March 2021 to June 2021 and as President from April 2019 to June 2021. Prior to April 2019, Mr. McCourt served as Ironwood's Senior Vice President of marketing and sales and Chief Commercial Officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from 2008 to 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he held a number of senior commercial roles, including Vice President of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra-Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager. Mr. McCourt serves on the board of trustees for the American Society of Gastrointestinal Endoscopy. Mr. McCourt previously served on the board of directors of Acceleron Pharma Inc. prior to its acquisition by Merck in November 2021. Mr. McCourt received a B.S. in Pharmacy from the University of Wisconsin.
- Steve Krognes
-
Steve Krognes，自2022年6月起担任董事会成员。Krognes先生是生物技术和生命科学领域的专业独立董事会成员。在加入董事会之前，Krognes先生于2015年10月至2022年4月在上市生物技术公司Denali Therapeutics Inc.担任首席财务官。Krognes先生从生物技术公司基因泰克加入Denali，曾于2009年4月至2015年9月担任首席财务官和执行委员会成员。Krognes先生还在2011年至2015年期间监督了Genentech的Site Services组织，并在2009年至2011年期间监督了Genentech的IT组织。他在2009年至2015年期间担任Genentech Access to Care基金会主席。2004年1月至2009年4月，Krognes先生在瑞士生物技术公司Roche Holding AG担任并购主管和财务执行委员会成员。2002年7月至2003年12月，Krognes先生在位于挪威的丹斯克银行担任并购总监。Krognes目前担任Denali Therapeutics Inc.、argenx SE和Pliant Therapeutics, Inc.的董事会成员，此前曾于2016年1月至2021年3月期间在Corvus制药，Inc.任职，于2016年1月至2023年1月期间在RLS Global AB任职，于2018年7月至2024年6月期间在Gritstone bio，Inc.任职。他获得了哈佛商学院的工商管理硕士学位和宾夕法尼亚大学沃顿商学院的经济学学士学位。
Steve Krognes,has served as a member of Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector.Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech's Site Services organization between 2011 and 2015, and Genentech's IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway.Mr. Krognes currently serves as a member of the Board of Directors at Denali Therapeutics Inc., argenx SE and Pliant Therapeutics, Inc., and previously served on the Board of Directors at Corvus Pharmaceuticals, Inc. between January 2016 and March 2021, RLS Global AB from January 2016 to January 2023 and Gritstone bio, Inc. from July 2018 to June 2024. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania. - Steve Krognes，自2022年6月起担任董事会成员。Krognes先生是生物技术和生命科学领域的专业独立董事会成员。在加入董事会之前，Krognes先生于2015年10月至2022年4月在上市生物技术公司Denali Therapeutics Inc.担任首席财务官。Krognes先生从生物技术公司基因泰克加入Denali，曾于2009年4月至2015年9月担任首席财务官和执行委员会成员。Krognes先生还在2011年至2015年期间监督了Genentech的Site Services组织，并在2009年至2011年期间监督了Genentech的IT组织。他在2009年至2015年期间担任Genentech Access to Care基金会主席。2004年1月至2009年4月，Krognes先生在瑞士生物技术公司Roche Holding AG担任并购主管和财务执行委员会成员。2002年7月至2003年12月，Krognes先生在位于挪威的丹斯克银行担任并购总监。Krognes目前担任Denali Therapeutics Inc.、argenx SE和Pliant Therapeutics, Inc.的董事会成员，此前曾于2016年1月至2021年3月期间在Corvus制药，Inc.任职，于2016年1月至2023年1月期间在RLS Global AB任职，于2018年7月至2024年6月期间在Gritstone bio，Inc.任职。他获得了哈佛商学院的工商管理硕士学位和宾夕法尼亚大学沃顿商学院的经济学学士学位。
- Steve Krognes,has served as a member of Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector.Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech's Site Services organization between 2011 and 2015, and Genentech's IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway.Mr. Krognes currently serves as a member of the Board of Directors at Denali Therapeutics Inc., argenx SE and Pliant Therapeutics, Inc., and previously served on the Board of Directors at Corvus Pharmaceuticals, Inc. between January 2016 and March 2021, RLS Global AB from January 2016 to January 2023 and Gritstone bio, Inc. from July 2018 to June 2024. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.
- Bernard Coulie
-
Bernard Coulie自2016年2月以来一直担任我们的首席执行官兼董事。在加入我们之前，Coulie博士共同创立了Actogenix N.V.，这是一家生物制药公司，并在该公司担任越来越重要的职务，包括从2006年9月到2015年2月担任Vice President研发、首席医疗官和首席执行官，该公司被Intrexon Corporation收购。在共同创立ActoGenix公司之前，Coulie博士曾在强生公司制药研究与开发欧洲公司担任多个职位，在药物发现和临床开发方面的责任越来越大。Coulie博士此前曾于2010年4月至2015年2月担任Actogenix的董事，并于2015年7月至2018年11月担任Biogazelle N.V.的董事。Coulie博士目前担任Calypso BV的董事和董事长。Coulie博士拥有比利时鲁汶大学（University of Leuven）的医学博士学位和博士学位，以及比利时鲁汶Vlerick管理学院（the Vlerick Management School，Belgium）的工商管理硕士学位。
Bernard Coulie,has served as a member of Septerna, Inc. board of directors since December 2023. Dr. Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical company, since February 2016. Prior to joining Pliant, Dr. Coulie co-founded ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing responsibility, including as Vice President R&D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to co-founding ActoGeniX, Dr. Coulie held various positions with increasing responsibility in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie is currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology company based in Belgium, and as a member of the board of directors of Charcot- Marie-Tooth Association, a non-profit patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. Dr. Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions, Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG (NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX (acquired by Intrexon Corporation) from April 2010 until February 2015. Dr. Coulie is a board-certified internist and received his M.D. and Ph.D. from the University of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven, Belgium. - Bernard Coulie自2016年2月以来一直担任我们的首席执行官兼董事。在加入我们之前，Coulie博士共同创立了Actogenix N.V.，这是一家生物制药公司，并在该公司担任越来越重要的职务，包括从2006年9月到2015年2月担任Vice President研发、首席医疗官和首席执行官，该公司被Intrexon Corporation收购。在共同创立ActoGenix公司之前，Coulie博士曾在强生公司制药研究与开发欧洲公司担任多个职位，在药物发现和临床开发方面的责任越来越大。Coulie博士此前曾于2010年4月至2015年2月担任Actogenix的董事，并于2015年7月至2018年11月担任Biogazelle N.V.的董事。Coulie博士目前担任Calypso BV的董事和董事长。Coulie博士拥有比利时鲁汶大学（University of Leuven）的医学博士学位和博士学位，以及比利时鲁汶Vlerick管理学院（the Vlerick Management School，Belgium）的工商管理硕士学位。
- Bernard Coulie,has served as a member of Septerna, Inc. board of directors since December 2023. Dr. Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical company, since February 2016. Prior to joining Pliant, Dr. Coulie co-founded ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing responsibility, including as Vice President R&D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to co-founding ActoGeniX, Dr. Coulie held various positions with increasing responsibility in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie is currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology company based in Belgium, and as a member of the board of directors of Charcot- Marie-Tooth Association, a non-profit patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. Dr. Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions, Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG (NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX (acquired by Intrexon Corporation) from April 2010 until February 2015. Dr. Coulie is a board-certified internist and received his M.D. and Ph.D. from the University of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven, Belgium.
- John Curnutte
-
John Curnutte自2017年8月以来一直担任我们的董事会成员。从2011年2月到2019年5月退休，Curnutte博士担任PortolaPharmaceuticals，Inc.研究与开发的执行Vice President，该公司是一家开发血栓和其他血液疾病候选产品的生物制药公司。他仍然担任Portola公司的顾问。在此之前，Curnutte博士担任3-V Biosciences，Inc.的首席执行官，这是一家生物技术公司。职业生涯早期，他曾担任先灵葆雅生物制药公司（Schering-Plough Biopharma）的总裁，此前曾在生物技术公司Genentech，Inc.担任过多个高级管理职位。任职Genentech公司之前，Curnutte博士曾担任Scripps Research Institute的终身教员，从事炎症生物化学和先天性免疫缺陷的分子遗传学的基础和临床研究。他曾担任Stanford University School of Medicine的儿科兼职临床教授，也曾担任医务人员（从1993年到2013年）。2015年5月至2016年6月，Curnutte博士担任心血管诊断公司Diadexus，Inc.的董事会成员。自2019年8月起，他担任Orchard Therapeutics（一家专注于体外自体骨髓基因治疗的公司）的董事会成员。Curnutte博士在哈佛大学（Harvard University）获得生物化学与分子生物学学士学位，并在哈佛医学院（Harvard Medical School）获得生物化学硕士学位和博士学位。
John Curnutte, has served as a member of our board of directors since August 2017. From February 2011 through his retirement in May 2019 Dr. Curnutte served as Executive Vice President of Research and Development at Portola Pharmaceuticals, Inc., a biopharmaceutical company developing product candidates for thrombosis and other hematologic diseases. He remains as a consultant to Portola/Alexion. Prior to that, Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company. Earlier in his career, he served as a President of Schering-Plough Biopharma and previously held several senior management positions at Genentech, Inc., a biotechnology company. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He was an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. From May 2015 to June 2016 Dr. Curnutte served as a member of the board of directors of Diadexus, Inc., a cardiovascular diagnostics company. Since August 2019 he has served as a member of the board of directors of Orchard Therapeutics, a company focused on hematopoietic stem cell gene therapy. Dr. Curnutte holds a B.S. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School. - John Curnutte自2017年8月以来一直担任我们的董事会成员。从2011年2月到2019年5月退休，Curnutte博士担任PortolaPharmaceuticals，Inc.研究与开发的执行Vice President，该公司是一家开发血栓和其他血液疾病候选产品的生物制药公司。他仍然担任Portola公司的顾问。在此之前，Curnutte博士担任3-V Biosciences，Inc.的首席执行官，这是一家生物技术公司。职业生涯早期，他曾担任先灵葆雅生物制药公司（Schering-Plough Biopharma）的总裁，此前曾在生物技术公司Genentech，Inc.担任过多个高级管理职位。任职Genentech公司之前，Curnutte博士曾担任Scripps Research Institute的终身教员，从事炎症生物化学和先天性免疫缺陷的分子遗传学的基础和临床研究。他曾担任Stanford University School of Medicine的儿科兼职临床教授，也曾担任医务人员（从1993年到2013年）。2015年5月至2016年6月，Curnutte博士担任心血管诊断公司Diadexus，Inc.的董事会成员。自2019年8月起，他担任Orchard Therapeutics（一家专注于体外自体骨髓基因治疗的公司）的董事会成员。Curnutte博士在哈佛大学（Harvard University）获得生物化学与分子生物学学士学位，并在哈佛医学院（Harvard Medical School）获得生物化学硕士学位和博士学位。
- John Curnutte, has served as a member of our board of directors since August 2017. From February 2011 through his retirement in May 2019 Dr. Curnutte served as Executive Vice President of Research and Development at Portola Pharmaceuticals, Inc., a biopharmaceutical company developing product candidates for thrombosis and other hematologic diseases. He remains as a consultant to Portola/Alexion. Prior to that, Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company. Earlier in his career, he served as a President of Schering-Plough Biopharma and previously held several senior management positions at Genentech, Inc., a biotechnology company. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He was an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. From May 2015 to June 2016 Dr. Curnutte served as a member of the board of directors of Diadexus, Inc., a cardiovascular diagnostics company. Since August 2019 he has served as a member of the board of directors of Orchard Therapeutics, a company focused on hematopoietic stem cell gene therapy. Dr. Curnutte holds a B.S. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School.
- Darren Cline
-
Darren Cline自2021年9月起担任我们的董事会成员。自2019年4月以来，他一直担任GW Pharmaceuticals的美国子公司Greenwich Bioscience的美国首席商务官兼执行委员会成员。在2010年10月至2019年3月期间，Cline先生担任Seattle Genetics, Inc.商业执行副总裁，负责所有市场营销，销售和管理市场。他曾直接参与Adcetris公司（基于抗体的生物制剂，FDA批准用于治疗某些血液学癌症）的上市的商业建设，并发挥了推动Adcetris公司持续增长的不可或缺的作用。加入Seattle Genetics之前，2006年10月至2009年10月，他曾任职Alexion Pharmaceuticals公司，在那里他曾担任Soliris公司的初始商业领导团队的一部分，帮助建立关键的销售职能。Cline先生在圣地亚哥州立大学获得本科学位，并在佩珀代因大学获得工商管理硕士学位。
Darren Cline has served as a member of board of directors since September 2021. Since April 2019 he has served as the U.S. Chief Commercial Officer and member of the Executive Committee for Greenwich Bioscience, the U.S. subsidiary of GW Pharmaceuticals. Between October 2010 and March 2019 Mr. Cline served as Executive Vice President, Commercial at Seattle Genetics, Inc., where he oversaw all marketing, sales, and managed markets. He was directly involved in the commercial build out for the launch of Adcetris, an antibody-based biologic the FDA approved for treatment of certain hematologic cancers and played an integral role driving Adcetris's continued growth. Prior to Seattle Genetics, between October 2006 and October 2009 Mr. Cline was at Alexion Pharmaceuticals, where he was part of the initial commercial leadership team for the Soliris launch, helping to build out key sales functions. Mr. Cline received his undergraduate degree from San Diego State University and his MBA from Pepperdine University. - Darren Cline自2021年9月起担任我们的董事会成员。自2019年4月以来，他一直担任GW Pharmaceuticals的美国子公司Greenwich Bioscience的美国首席商务官兼执行委员会成员。在2010年10月至2019年3月期间，Cline先生担任Seattle Genetics, Inc.商业执行副总裁，负责所有市场营销，销售和管理市场。他曾直接参与Adcetris公司（基于抗体的生物制剂，FDA批准用于治疗某些血液学癌症）的上市的商业建设，并发挥了推动Adcetris公司持续增长的不可或缺的作用。加入Seattle Genetics之前，2006年10月至2009年10月，他曾任职Alexion Pharmaceuticals公司，在那里他曾担任Soliris公司的初始商业领导团队的一部分，帮助建立关键的销售职能。Cline先生在圣地亚哥州立大学获得本科学位，并在佩珀代因大学获得工商管理硕士学位。
- Darren Cline has served as a member of board of directors since September 2021. Since April 2019 he has served as the U.S. Chief Commercial Officer and member of the Executive Committee for Greenwich Bioscience, the U.S. subsidiary of GW Pharmaceuticals. Between October 2010 and March 2019 Mr. Cline served as Executive Vice President, Commercial at Seattle Genetics, Inc., where he oversaw all marketing, sales, and managed markets. He was directly involved in the commercial build out for the launch of Adcetris, an antibody-based biologic the FDA approved for treatment of certain hematologic cancers and played an integral role driving Adcetris's continued growth. Prior to Seattle Genetics, between October 2006 and October 2009 Mr. Cline was at Alexion Pharmaceuticals, where he was part of the initial commercial leadership team for the Soliris launch, helping to build out key sales functions. Mr. Cline received his undergraduate degree from San Diego State University and his MBA from Pepperdine University.
- Katharine Knobil
-
Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School. - Katharine Knobil，此前于2021年4月至2024年1月担任实验室产品和软件公司安捷伦科技公司的首席医疗官。此前，Knobil博士曾于2018年12月至2021年1月在Kaleido Biosciences, Inc.担任首席医疗官兼研发主管，该公司是一家临床阶段的医疗保健公司，目标是利用微生物组治疗疾病和改善健康。Knobil博士在制药公司葛兰素史克（GSK）担任越来越多的职责20多年，最近于2017年12月至2018年12月担任公司首席医疗官，负责监督制药、疫苗和消费者业务的医疗事务、健康结果、全球临床安全和医疗治理。此前，她曾于2015年11月至2017年12月担任GSK制药部门的首席医疗官，在此之前，她担任高级副总裁、价值证据和结果。Knobil博士于1997年首次加入GSK，担任呼吸临床开发的研究医师，随后担任多个职务，包括领导欧洲呼吸临床团队，以及在中国建设所有治疗领域的后期临床开发。Knobil博士被FiercePharma评为2018年生命科学领域最激烈的女性之一。Knobil博士目前担任Marker Therapeutics, Inc.（纳斯达克：MRKR）的董事会成员，自2021年12月起担任Pliant Therapeutics, Inc.（纳斯达克：PLRX）的董事会成员，自2022年9月起担任Nimbus Therapeutics，LLC的董事会成员，自2024年2月起担任Infinant Health，Inc.的董事会成员，自2025年3月起担任。从2020年6月到2022年3月，她一直是阿里那制药公司的董事会成员，直到该公司被辉瑞收购。Knobil博士获得了康奈尔大学的学士学位、得克萨斯大学西南医学院的医学博士学位，并在约翰霍普金斯医学院完成了肺部和重症医学的研究金。
- Katharine Knobil joined the Board in December 2021. Dr. Knobil currently serves as Chief Medical Officer at Altesa BioSciences, Inc. and previoly served as Chief Medical Officer of Agilent Technologies Inc., a position she held from April 2021 to January 2024. Dr. Knobil previoly served as Chief Medical Officer and Head of Research & Development at Kaleido Biosciences, Inc. from December 2018 to January 2021. Previoly, Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline plc, most recently serving as the corporate Chief Medical Officer from 2017 to December 2018, and as Chief Medical Officer for Pharmaceuticals at GSK from 2015 to 2017. She served as a member of the board of directors of Arena Pharmaceuticals, Inc. from June 2020 until its acquisition by Pfizer Inc. in March 2022. Dr. Knobil currently serves on the Board of Directors of Nimb Therapeutics, LLC, KorroBio, Inc. and Pliant Therapeutics, Inc. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southstern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.
- Hoyoung Huh
-
Hoyoung Huh，2011年9月以来担任董事会主席，2011年2月到2011年9月担任执行董事长。2010年5月以来，担任Geron董事。他是一家新兴的医疗技术公司Cytomx Therapeutics的董事会主席。Huh博士也是一家制药开发公司ADDEX Pharmaceuticals，和一家糖尿病市场开发新型药物的生物制药公司AntriaBio的董事。2008年2月到2011年11月，Huh博士是一家专注于在心脏病、肿瘤、中枢神经系统疾病、代谢性疾病、眼科和疫苗方面开发治疗方法的全球制药Sanofi-Aventis全资所有的子公司BiPar Sciences的董事会主席，2009年BiPar和Sanofi-Aventis，整合，2008年2月到2009年12月，也担任BiPar的总裁和首席执行官。此外，Huh博士担任几个私营公司的董事会成员。Huh博士2009年9月到2010年4月，担任一家致力于发现、开发、制造和营销药品和医疗产品，包括营养品、设备和诊断的全球潜力健康医疗公司雅培全资子公司Facet Biotech的董事会成员。2008年2月到2009年5月，他是一家为肿瘤学、疼痛、抗感染、抗病毒和免疫学做准备，开发小分子药品、缩氨酸和其它生物技术药品，处于临床阶段的生物制药公司Nektar Therapeutics的董事会成员。2005年3月到2008年2月，Huh博士担任Nektar的首席运营官以及商业开发和营销的高级副总裁，在那里，他负责公司全球业务开发、营销和制造，领导Nektar的聚乙二醇化项目。在加入Nektar之前，Huh博士是一家全球管理咨询公司McKinsey & Company的合伙人，在那里，他负责生物技术和生物制药部门。在加入McKinsey之前，他在康乃尔大学医学院和Sloan-Kettering癌症中心担任医生和研究员。Huh博士拥有达特茅斯学院生物化学学士学位，以及康乃尔大学医学院遗传学和细胞生物学以及Sloan-Kettering协会的医学博士和博士学位。
Hoyoung Huh has served as Chairman of Akari Therapeutics, Plc's board of directors since November 2024, following Akari Therapeutics, Plc's merger with Peak Bio, Inc. Dr. Huh is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. Dr. Huh is a Silicon Valley based entrepreneur and investor in healthcare and technology based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh has been involved in the formation and management of multiple biotechnology and innovation based companies, including holding board positions. He previously served as the Chairman of the board of directors of Geron Corporation from September 2011 to December 2018 and CytomX Therapeutics, Inc. from February 2012 to December 2018 and served as a member of the board of directors of Rezolute, Inc. (f/k/a AntriaBio, Inc.) from 2013 to January 2019. He holds an A.B. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology and Genetics from Cornell University Sloan Kettering Institute. - Hoyoung Huh，2011年9月以来担任董事会主席，2011年2月到2011年9月担任执行董事长。2010年5月以来，担任Geron董事。他是一家新兴的医疗技术公司Cytomx Therapeutics的董事会主席。Huh博士也是一家制药开发公司ADDEX Pharmaceuticals，和一家糖尿病市场开发新型药物的生物制药公司AntriaBio的董事。2008年2月到2011年11月，Huh博士是一家专注于在心脏病、肿瘤、中枢神经系统疾病、代谢性疾病、眼科和疫苗方面开发治疗方法的全球制药Sanofi-Aventis全资所有的子公司BiPar Sciences的董事会主席，2009年BiPar和Sanofi-Aventis，整合，2008年2月到2009年12月，也担任BiPar的总裁和首席执行官。此外，Huh博士担任几个私营公司的董事会成员。Huh博士2009年9月到2010年4月，担任一家致力于发现、开发、制造和营销药品和医疗产品，包括营养品、设备和诊断的全球潜力健康医疗公司雅培全资子公司Facet Biotech的董事会成员。2008年2月到2009年5月，他是一家为肿瘤学、疼痛、抗感染、抗病毒和免疫学做准备，开发小分子药品、缩氨酸和其它生物技术药品，处于临床阶段的生物制药公司Nektar Therapeutics的董事会成员。2005年3月到2008年2月，Huh博士担任Nektar的首席运营官以及商业开发和营销的高级副总裁，在那里，他负责公司全球业务开发、营销和制造，领导Nektar的聚乙二醇化项目。在加入Nektar之前，Huh博士是一家全球管理咨询公司McKinsey & Company的合伙人，在那里，他负责生物技术和生物制药部门。在加入McKinsey之前，他在康乃尔大学医学院和Sloan-Kettering癌症中心担任医生和研究员。Huh博士拥有达特茅斯学院生物化学学士学位，以及康乃尔大学医学院遗传学和细胞生物学以及Sloan-Kettering协会的医学博士和博士学位。
- Hoyoung Huh has served as Chairman of Akari Therapeutics, Plc's board of directors since November 2024, following Akari Therapeutics, Plc's merger with Peak Bio, Inc. Dr. Huh is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. Dr. Huh is a Silicon Valley based entrepreneur and investor in healthcare and technology based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh has been involved in the formation and management of multiple biotechnology and innovation based companies, including holding board positions. He previously served as the Chairman of the board of directors of Geron Corporation from September 2011 to December 2018 and CytomX Therapeutics, Inc. from February 2012 to December 2018 and served as a member of the board of directors of Rezolute, Inc. (f/k/a AntriaBio, Inc.) from 2013 to January 2019. He holds an A.B. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology and Genetics from Cornell University Sloan Kettering Institute.
- Gayle Crowell
-
Gayle Crowell，担任Envestnet, Inc.董事会成员，该职务自2016年3月起担任。在此之前，她于2014年3月起担任Yodlee，Inc.的首席独立董事，并于2002年7月起担任Yodlee，Inc.董事会成员，直至2015年11月19日Yodlee，Inc.被Envestnet收购。Crowell女士于2001年6月至2019年1月担任私募股权公司Warburg Pincus LLC的运营业务顾问。从2000年1月至2001年6月，Crowell女士担任Epiphany，Inc.的总裁，该公司是一家客户关系管理软件开发商，于2005年9月被SSA Global Technologies，Inc.收购。Crowell女士目前还担任Hercules Technology Growth Capital的董事会成员，该公司自2019年2月4日起担任财务和风险管理平台提供商GTreasury的董事会成员，自2021年4月14日起担任该公司的董事会成员，自2020年8月起担任物业管理SaaS平台提供商ResMan的董事会成员。Crowell女士作为公共和私人董事会成员拥有丰富的董事经验，曾担任超过25家公共和私营公司的董事长、首席董事或独立董事，为客户、员工和股东等推动最高级别的价值创造。Crowell获得了内华达大学里诺分校的教育本科学位。
Gayle Crowell serves as a member of the board of directors of Envestnet, Inc., a role she has held since March 2016. Prior to that she served as lead independent director of Yodlee, Inc. from March 2014 and as a member of the Yodlee, Inc. board of directors from July 2002 until November 19 2015 when Yodlee, Inc. was acquired by Envestnet. Ms. Crowell served as an operational business consultant for Warburg Pincus LLC, a private equity firm, from June 2001 to January 2019. From January 2000 to June 2001 Ms. Crowell served as president of Epiphany, Inc., a developer of customer relationship management software which was acquired by SSA Global Technologies, Inc. in September 2005. Ms. Crowell also currently serves on the board of directors of Hercules Technology Growth Capital since February 4 2019 GTreasury, a treasury and risk management platform provider, since April 14 2021 and ResMan, a property management SaaS platform provider, since August 2020. Ms. Crowell has extensive director experience as a public and private board member, having served as a chairperson, lead director or independent director for over twenty five public and private corporations driving value creation at the highest level for customers, employees and shareholders alike.Ms. Crowell received an undergraduate degree in education from the University of Nevada at Reno. - Gayle Crowell，担任Envestnet, Inc.董事会成员，该职务自2016年3月起担任。在此之前，她于2014年3月起担任Yodlee，Inc.的首席独立董事，并于2002年7月起担任Yodlee，Inc.董事会成员，直至2015年11月19日Yodlee，Inc.被Envestnet收购。Crowell女士于2001年6月至2019年1月担任私募股权公司Warburg Pincus LLC的运营业务顾问。从2000年1月至2001年6月，Crowell女士担任Epiphany，Inc.的总裁，该公司是一家客户关系管理软件开发商，于2005年9月被SSA Global Technologies，Inc.收购。Crowell女士目前还担任Hercules Technology Growth Capital的董事会成员，该公司自2019年2月4日起担任财务和风险管理平台提供商GTreasury的董事会成员，自2021年4月14日起担任该公司的董事会成员，自2020年8月起担任物业管理SaaS平台提供商ResMan的董事会成员。Crowell女士作为公共和私人董事会成员拥有丰富的董事经验，曾担任超过25家公共和私营公司的董事长、首席董事或独立董事，为客户、员工和股东等推动最高级别的价值创造。Crowell获得了内华达大学里诺分校的教育本科学位。
- Gayle Crowell serves as a member of the board of directors of Envestnet, Inc., a role she has held since March 2016. Prior to that she served as lead independent director of Yodlee, Inc. from March 2014 and as a member of the Yodlee, Inc. board of directors from July 2002 until November 19 2015 when Yodlee, Inc. was acquired by Envestnet. Ms. Crowell served as an operational business consultant for Warburg Pincus LLC, a private equity firm, from June 2001 to January 2019. From January 2000 to June 2001 Ms. Crowell served as president of Epiphany, Inc., a developer of customer relationship management software which was acquired by SSA Global Technologies, Inc. in September 2005. Ms. Crowell also currently serves on the board of directors of Hercules Technology Growth Capital since February 4 2019 GTreasury, a treasury and risk management platform provider, since April 14 2021 and ResMan, a property management SaaS platform provider, since August 2020. Ms. Crowell has extensive director experience as a public and private board member, having served as a chairperson, lead director or independent director for over twenty five public and private corporations driving value creation at the highest level for customers, employees and shareholders alike.Ms. Crowell received an undergraduate degree in education from the University of Nevada at Reno.
高管简历
中英对照 | 中文 | 英文- Bernard Coulie
Bernard Coulie自2016年2月以来一直担任我们的首席执行官兼董事。在加入我们之前，Coulie博士共同创立了Actogenix N.V.，这是一家生物制药公司，并在该公司担任越来越重要的职务，包括从2006年9月到2015年2月担任Vice President研发、首席医疗官和首席执行官，该公司被Intrexon Corporation收购。在共同创立ActoGenix公司之前，Coulie博士曾在强生公司制药研究与开发欧洲公司担任多个职位，在药物发现和临床开发方面的责任越来越大。Coulie博士此前曾于2010年4月至2015年2月担任Actogenix的董事，并于2015年7月至2018年11月担任Biogazelle N.V.的董事。Coulie博士目前担任Calypso BV的董事和董事长。Coulie博士拥有比利时鲁汶大学（University of Leuven）的医学博士学位和博士学位，以及比利时鲁汶Vlerick管理学院（the Vlerick Management School，Belgium）的工商管理硕士学位。
Bernard Coulie,has served as a member of Septerna, Inc. board of directors since December 2023. Dr. Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical company, since February 2016. Prior to joining Pliant, Dr. Coulie co-founded ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing responsibility, including as Vice President R&D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to co-founding ActoGeniX, Dr. Coulie held various positions with increasing responsibility in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie is currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology company based in Belgium, and as a member of the board of directors of Charcot- Marie-Tooth Association, a non-profit patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. Dr. Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions, Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG (NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX (acquired by Intrexon Corporation) from April 2010 until February 2015. Dr. Coulie is a board-certified internist and received his M.D. and Ph.D. from the University of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven, Belgium.- Bernard Coulie自2016年2月以来一直担任我们的首席执行官兼董事。在加入我们之前，Coulie博士共同创立了Actogenix N.V.，这是一家生物制药公司，并在该公司担任越来越重要的职务，包括从2006年9月到2015年2月担任Vice President研发、首席医疗官和首席执行官，该公司被Intrexon Corporation收购。在共同创立ActoGenix公司之前，Coulie博士曾在强生公司制药研究与开发欧洲公司担任多个职位，在药物发现和临床开发方面的责任越来越大。Coulie博士此前曾于2010年4月至2015年2月担任Actogenix的董事，并于2015年7月至2018年11月担任Biogazelle N.V.的董事。Coulie博士目前担任Calypso BV的董事和董事长。Coulie博士拥有比利时鲁汶大学（University of Leuven）的医学博士学位和博士学位，以及比利时鲁汶Vlerick管理学院（the Vlerick Management School，Belgium）的工商管理硕士学位。
- Bernard Coulie,has served as a member of Septerna, Inc. board of directors since December 2023. Dr. Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical company, since February 2016. Prior to joining Pliant, Dr. Coulie co-founded ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing responsibility, including as Vice President R&D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to co-founding ActoGeniX, Dr. Coulie held various positions with increasing responsibility in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie is currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology company based in Belgium, and as a member of the board of directors of Charcot- Marie-Tooth Association, a non-profit patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. Dr. Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions, Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG (NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX (acquired by Intrexon Corporation) from April 2010 until February 2015. Dr. Coulie is a board-certified internist and received his M.D. and Ph.D. from the University of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven, Belgium.
- Keith Cummings
Keith Cummings自2018年12月起担任我们的首席财务官。在加入我们之前，卡明斯博士于2014年9月至2018年12月担任花旗集团全球市场投资银行梦百合集团董事。在加入花旗集团之前，2009年8月至2014年9月，卡明斯博士先后在雷曼兄弟（Lehman Brothers）和巴克莱投资银行（Barclays Investment Bank）任职，担任投资银行业务Vice President。他持有North Carolina State University的生物化学学士学位、Duke University’；s Fuqua School of Business的工商管理硕士学位，以及Duke University School of Medicine的医学博士学位。
Keith Cummings, has served as our Chief Financial Officer since December 2018. Prior to joining Pliant, Dr. Cummings served as a Director in the Investment Banking Healthcare Group at Citigroup Global Markets from September 2014 until December 2018. Prior to joining Citigroup, Dr. Cummings worked at Lehman Brothers and, subsequently, at Barclays Investment Bank from August 2009 to September 2014 where he served as a vice president of investment banking. He holds a B.S. in Biochemistry from North Carolina State University, an MBA from Duke University's Fuqua School of Business and an M.D. from Duke University School of Medicine.- Keith Cummings自2018年12月起担任我们的首席财务官。在加入我们之前，卡明斯博士于2014年9月至2018年12月担任花旗集团全球市场投资银行梦百合集团董事。在加入花旗集团之前，2009年8月至2014年9月，卡明斯博士先后在雷曼兄弟（Lehman Brothers）和巴克莱投资银行（Barclays Investment Bank）任职，担任投资银行业务Vice President。他持有North Carolina State University的生物化学学士学位、Duke University’；s Fuqua School of Business的工商管理硕士学位，以及Duke University School of Medicine的医学博士学位。
- Keith Cummings, has served as our Chief Financial Officer since December 2018. Prior to joining Pliant, Dr. Cummings served as a Director in the Investment Banking Healthcare Group at Citigroup Global Markets from September 2014 until December 2018. Prior to joining Citigroup, Dr. Cummings worked at Lehman Brothers and, subsequently, at Barclays Investment Bank from August 2009 to September 2014 where he served as a vice president of investment banking. He holds a B.S. in Biochemistry from North Carolina State University, an MBA from Duke University's Fuqua School of Business and an M.D. from Duke University School of Medicine.
- Lily Cheung
Lily Cheung，自2023年1月起担任Pliant Therapeutics, Inc.首席人力资源官。在加入Pliant之前，张女士从2021年12月起担任临床阶段生物技术公司Synthekine的人力资源副总裁。此前，她曾于2020年1月至2021年12月在商业生物制药公司里格尔制药担任人力资源副总裁，在此之前于2018年5月至2020年1月担任人力资源运营执行董事。在加入Rigel之前，她在Actelion Pharmaceuticals，Inc.（现为Janssen Pharmaceuticals，系强生旗下公司）任职，自2006年以来，她在该公司担任的职位责任越来越大，最近一次是自2015年起担任人力资源高级总监。在Actelion之前，张女士在Covad Communications服务了六年，领导人力资源运营团队。张女士还曾在美国国家半导体公司（National Semiconductor）和联合医疗集团（UnitedHealthcare）任职。她在旧金山州立大学获得管理学学士学位。
Lily Cheung,has served as Pliant Therapeutics, Inc. Chief Human Resources Officer since January 2023. Prior to joining Pliant, Ms. Cheung was the Vice President of Human Resources at Synthekine, a clinical-stage biotech company, from December 2021. Previously, she served as Vice President of Human Resources at Rigel Pharmaceuticals, a commercial biopharmaceutical company, from January 2020 until December 2021 and before that as Executive Director, HR Operations from May 2018 to January 2020. Prior to joining Rigel, she was with Actelion Pharmaceuticals, Inc. (now Janssen Pharmaceuticals, a Johnson & Johnson Company), where she held positions of increasing responsibilities since 2006, most recently as Senior Director Human Resources since 2015. Before Actelion, Ms. Cheung served six years at Covad Communications leading the HR Operations team. Ms. Cheung has also held positions at National Semiconductor and UnitedHealthcare. She received her B.S. in Management from San Francisco State University.- Lily Cheung，自2023年1月起担任Pliant Therapeutics, Inc.首席人力资源官。在加入Pliant之前，张女士从2021年12月起担任临床阶段生物技术公司Synthekine的人力资源副总裁。此前，她曾于2020年1月至2021年12月在商业生物制药公司里格尔制药担任人力资源副总裁，在此之前于2018年5月至2020年1月担任人力资源运营执行董事。在加入Rigel之前，她在Actelion Pharmaceuticals，Inc.（现为Janssen Pharmaceuticals，系强生旗下公司）任职，自2006年以来，她在该公司担任的职位责任越来越大，最近一次是自2015年起担任人力资源高级总监。在Actelion之前，张女士在Covad Communications服务了六年，领导人力资源运营团队。张女士还曾在美国国家半导体公司（National Semiconductor）和联合医疗集团（UnitedHealthcare）任职。她在旧金山州立大学获得管理学学士学位。
- Lily Cheung,has served as Pliant Therapeutics, Inc. Chief Human Resources Officer since January 2023. Prior to joining Pliant, Ms. Cheung was the Vice President of Human Resources at Synthekine, a clinical-stage biotech company, from December 2021. Previously, she served as Vice President of Human Resources at Rigel Pharmaceuticals, a commercial biopharmaceutical company, from January 2020 until December 2021 and before that as Executive Director, HR Operations from May 2018 to January 2020. Prior to joining Rigel, she was with Actelion Pharmaceuticals, Inc. (now Janssen Pharmaceuticals, a Johnson & Johnson Company), where she held positions of increasing responsibilities since 2006, most recently as Senior Director Human Resources since 2015. Before Actelion, Ms. Cheung served six years at Covad Communications leading the HR Operations team. Ms. Cheung has also held positions at National Semiconductor and UnitedHealthcare. She received her B.S. in Management from San Francisco State University.
- Minnie Kuo
Minnie Kuo，于2023年9月加入公司，担任首席发展官，并一直担任该职位，直至被任命为首席运营官。她是一位经验丰富的生物技术和制药高管，带来了20多年的多国临床开发经验，涉及呼吸、肿瘤、神经退行性疾病、炎症和传染病等多个治疗领域。郭女士从Vir Biotechnology加入Pliant，在那里她担任的角色越来越重要，最近担任转化和临床开发运营高级副总裁。在该职位上，她领导了整个临床组合的业务运营、临床运营和组织规划。在加入VR之前，郭女士曾在内克塔治疗和吉利德科学担任高级临床运营职务。在吉利德，她负责监督公司炎症和肝脏产品组合中多个化合物和适应症的战略方向。在其职业生涯的早期，郭女士曾在罗氏/基因泰克以及包括ICON和PharmaNet在内的临床研究组织担任全球项目管理和临床研究管理职务。郭女士在加州大学圣地亚哥分校获得文学学士学位，并在旧金山大学获得理学硕士学位。
Minnie Kuo,joined the Company in September 2023 as Chief Development Officer and served in such position until her appointment as Chief Operating Officer. Ms. Kuo joined Pliant from Vir Biotechnology where she held roles of increasing responsibilities, most recently serving as Senior Vice President of Translational and Clinical Development Operations. In that role, she led business operations, clinical operations, and organizational planning across the entire clinical portfolio. Prior to Vir, Ms. Kuo held senior clinical operations roles at Nektar Therapeutics and Gilead Sciences. At Gilead, she oversaw the strategic direction of multiple compounds and indications within the company's inflammation and hepatic portfolios. Earlier in her career, Ms. Kuo held global project management and clinical study management roles at Roche/Genentech and at clinical research organizations including ICON and PharmaNet. Ms. Kuo received her Bachelor of Arts from the University of California, San Diego, and a Masters of Science from the University of San Francisco.- Minnie Kuo，于2023年9月加入公司，担任首席发展官，并一直担任该职位，直至被任命为首席运营官。她是一位经验丰富的生物技术和制药高管，带来了20多年的多国临床开发经验，涉及呼吸、肿瘤、神经退行性疾病、炎症和传染病等多个治疗领域。郭女士从Vir Biotechnology加入Pliant，在那里她担任的角色越来越重要，最近担任转化和临床开发运营高级副总裁。在该职位上，她领导了整个临床组合的业务运营、临床运营和组织规划。在加入VR之前，郭女士曾在内克塔治疗和吉利德科学担任高级临床运营职务。在吉利德，她负责监督公司炎症和肝脏产品组合中多个化合物和适应症的战略方向。在其职业生涯的早期，郭女士曾在罗氏/基因泰克以及包括ICON和PharmaNet在内的临床研究组织担任全球项目管理和临床研究管理职务。郭女士在加州大学圣地亚哥分校获得文学学士学位，并在旧金山大学获得理学硕士学位。
- Minnie Kuo,joined the Company in September 2023 as Chief Development Officer and served in such position until her appointment as Chief Operating Officer. Ms. Kuo joined Pliant from Vir Biotechnology where she held roles of increasing responsibilities, most recently serving as Senior Vice President of Translational and Clinical Development Operations. In that role, she led business operations, clinical operations, and organizational planning across the entire clinical portfolio. Prior to Vir, Ms. Kuo held senior clinical operations roles at Nektar Therapeutics and Gilead Sciences. At Gilead, she oversaw the strategic direction of multiple compounds and indications within the company's inflammation and hepatic portfolios. Earlier in her career, Ms. Kuo held global project management and clinical study management roles at Roche/Genentech and at clinical research organizations including ICON and PharmaNet. Ms. Kuo received her Bachelor of Arts from the University of California, San Diego, and a Masters of Science from the University of San Francisco.